Skip to content

MEdical Versus SUrgical Treatments of Rectal Endometriosis

Randomized Trial Comparing Functional Digestive Outcomes Related to Two Types of Management of Rectal Endometriosis: Continuous Hormonal Treatment and Curative Surgery

Status
Completed
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01973816
Acronym
MESURE
Enrollment
78
Registered
2013-11-01
Start date
2014-09-09
Completion date
2022-10-11
Last updated
2026-01-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometriosis

Keywords

deep endometriosis;, rectal endometriosis;, rectal shaving;, colorectal resection;, bowel endometriosis

Brief summary

The purpose of this study is to determine whether, in women with deep endometriosis involving the rectum and not intending to get pregnant, continuous hormonal treatment would be followed by better digestive functional outcomes than curative rectal surgery. Are included women from 35 to 50 years presenting with deep endometriosis infiltrating at least the muscular layer of the rectum and not having pregnancy intention. The main outcome concerns the quality of digestive function 24 after the onset of the treatment, assessed using a composite variable: patient considering that digestive function is normal AND the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) \<7 AND the Gastrointestinal Quality of Life Index (GIQLI) score \>100. Secondary outcomes are: presence of severe constipation, increased frequency of daily bowel movements, anal incontinence, postoperative dysuria, Biberoglou & Behrman score, quality of life SF36 score, KESS score, GIQLI, Wexner score of anal continence, Bristol stools score, the rate of postoperative complications, medical treatment adverse outcomes, the rate of additional endoscopic and surgical procedures. The randomization is central, once the physician asses the diagnosis, explain the study's principle and rece In the arm A, the patients received triptoreline and add back therapy by estradiol during 6 months, followed by daily intake of cyproterone acetate and add back therapy during 18 months. In the arm B, patients are managed by rectal surgery (depending on the surgeon choice: rectal shaving, rectal disc excision or colorectal resection) followed by the prevention of recurrences by daily intake of cyproterone acetate and add back therapy during 18 months. The number of subjects required is 78 (39 on each arm). Inclusions period is estimated at 24 months. The length of the follow up is 24 months. The patients have 8 visits in the arm A, and 7 visits in the arm B. Eleven French tertiary referral centres will enrol patients in the trial.

Interventions

DRUGTriptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;

Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months

PROCEDURErectal shaving; rectal disc excision; colorectal resection
DRUGCyproterone acetate 50 mg; estradiol 0.5% percutaneous

Daily intake for 18 months

DRUGEstradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral

Daily intake during 24 months

Sponsors

University Hospital, Rouen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Eligibility

Sex/Gender
FEMALE
Age
35 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Age 35-50 * No menopause * Digestive complaints: defecation pain, dyskesia, diarrhea, constipation, rectorrhage * Imaging assessment revealing deep endometriosis involving at least the muscular rectal layer * No intention to get pregnant during the following 24 months * Negative urinary pregnancy test * Affiliated to the French Social Security System

Exclusion criteria

* Pregnant women or during the breastfeeding * Pregnancy intention or lack of efficient contraception * Unexpected rectal endometriosis intraoperatively revealed * Refus of one of treatments planned in the two arms * Severe disease requiring surgical treatment in emergency (bowel occlusion, ureteral stenosis or hydronephrosis), severe dyspareunia * Contraindications to hormonal treatment or surgery * Major thromboembolic factors * Antecedents of inflammatory bowel diseases, cancer or colorectal resection * Vaginal hemorrhage with undetermined etiology

Design outcomes

Primary

MeasureTime frameDescription
Postoperative digestive function24 monthsComposite variable: patient considering that digestive function is normal AND the Knowles-Eccersley-Scott-Symptom Questionnaire (KESS score) \<7 AND the Gastrointestinal Quality of Life Index (GIQLI) score \>100.

Secondary

MeasureTime frameDescription
Unfavorable digestive functional outcome24 monthsPresence of severe constipation (\<1 stool/5D), increased frequency of daily bowel movements (\>=3 stools/D), anal incontinence, postoperative dysuria

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026